Monopar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Monopar Therapeutics

10/08/2023 14:06

* Monopar Therapeutics Inc  MNPR.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 18 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Monopar Therapeutics Inc's reported EPS for the quarter
was a
loss of 16 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Monopar Therapeutics Inc shares had fallen by 15.1% this
quarter and lost 69.4% so far this year.
    * The company reported a quarterly loss of $2.2 million.
    * Wall Street's median 12-month price target for Monopar
Therapeutics Inc is $3.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 01:06 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.18          -0.16          Beat
 Mar. 31 2023      -0.22          -0.19          Beat
 Dec. 31 2022      -0.20          -0.23          Missed
 Sep. 30 2022      -0.22          -0.19          Beat